开窗/分支支架主动脉腔内修复术后抗血小板与抗凝治疗实践模式
基于美国主动脉研究联盟10项医师发起研究2012—2023年连续入组的1525例开窗/分支支架主动脉腔内修复术后患者,分析出院抗栓方案与1年结局。各方案间出血、生存及再干预无差异,但双联抗血小板治疗组靶动脉通畅率优于单联抗血小板治疗(HR 0.48)。
要点
- 出院时双联抗血小板治疗占49.6%,单联抗血小板治疗占28.8%。
- 双联抗血小板治疗与靶动脉通畅丧失风险降低相关(HR 0.48)。
- 各抗栓方案间1年生存、出血及再干预率无显著差异。
核心结论
- 开窗/分支支架主动脉腔内修复术后抗血小板与抗凝方案在美国主动脉研究联盟内差异很大。
- 不同方案间出血并发症、生存率或再干预率无差异,但双联抗血小板治疗组分支血管通畅率更高。
- 作者认为这些数据提示双联抗血小板治疗有益,但该发现的普遍性受回顾性数据性质限制,临床意义不明确。
- 作者认为无法明确最佳方案及其持续时间,提示可在该队列内嵌套随机试验以确定最有效的抗血小板/抗凝方案。
研究设计与样本
- 研究为美国主动脉研究联盟10项独立医师发起的研究性器械豁免研究2012—2023年连续入组患者的评估。
- 共1525例具有完整暴露和结局数据的患者纳入分析。
- 按指数开窗/分支支架主动脉腔内修复术出院时用药方案分组:单联抗血小板治疗(阿司匹林单用或P2Y12抑制剂单用)、单用抗凝药、双联抗血小板治疗(阿司匹林+P2Y12抑制剂)、单联抗血小板治疗+抗凝药(阿司匹林+抗凝药或P2Y12抑制剂+抗凝药)、三联治疗(阿司匹林+P2Y12抑制剂+抗凝药)及无治疗。
- 采用Kaplan-Meier分析和Cox比例风险模型比较1年结局,包括生存、靶动脉通畅、无出血并发症、无任何再干预及无支架特异性再干预。
主要发现
- 出院时双联抗血小板治疗占49.6%,单联抗血小板治疗占28.8%,单联抗血小板治疗+抗凝药占13.6%,三联治疗占3.2%,单用抗凝药占2.6%,无治疗占2.2%。
- 出院用药方案与1年生存、出血并发症、复合再干预率或支架特异性再干预率差异无关。
- 1年靶动脉通畅率存在显著差异;多变量分析中与单联抗血小板治疗相比,双联抗血小板治疗靶动脉通畅丧失风险更低(HR 0.48;95%CI 0.27-0.84;P=0.01)。
- 仅肾支架或仅内脏支架亚组分析中,双联抗血小板治疗靶动脉通畅丧失风险不再显著更低(肾:HR 0.66;95%CI 0.35-1.27;P=0.22;内脏:HR 0.31;95%CI 0.05-1.9;P=0.21)。
- 双联抗血小板治疗持续时间(1个月、6个月或1年)对靶动脉通畅无显著影响。
关键数值与推荐
- 与单联抗血小板治疗相比,双联抗血小板治疗靶动脉通畅丧失风险更低(HR 0.48;95%CI 0.27-0.84;P=0.01)。
- 肾支架亚组中双联抗血小板治疗与单联抗血小板治疗相比靶动脉通畅丧失风险无显著差异(HR 0.66;95%CI 0.35-1.27;P=0.22)。
- 内脏支架亚组中双联抗血小板治疗与单联抗血小板治疗相比靶动脉通畅丧失风险无显著差异(HR 0.31;95%CI 0.05-1.9;P=0.21)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为这些数据提示双联抗血小板治疗有益,但该发现的普遍性受回顾性数据性质限制,临床意义不明确。
- 作者认为无法明确最佳方案及其持续时间,提示可在该队列内嵌套随机试验。
局限性
- 作者指出该发现的普遍性受回顾性数据性质限制。
- 作者指出该发现的临床意义不明确,因为不同方案间生存、出血或再干预率无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Antiplatelet and/or anticoagulant therapy are commonly prescribed after fenestrated/branched endovascular aortic repair (F/BEVAR). However, the optimal regimen remains unknown. We sought to characterize practice patterns and outcomes of antiplatelet and anticoagulant use in patients who underwent F/BEVAR. METHODS: Consecutive patients enrolled (2012-2023) as part of the United States Aortic Research Consortium (US-ARC) from 10 independent physician-sponsored investigational device exemption studies were evaluated. The cohort was characterized by medication regimen on discharge from index F/BEVAR: (1) Aspirin alone OR P2Y12 alone (single-antiplatelet therapy [SAPT]); (2) Anticoagulant alone; (3) Aspirin + P2Y12 (dual-antiplatelet therapy [DAPT]); (4) Aspirin + anticoagulant OR P2Y12 + anticoagulant (SAPT + anticoagulant); (5) Aspirin + P2Y12 + anticoagulant (triple therapy [TT]); and (6) No therapy. Kaplan-Meier analysis and Cox proportional hazards modeling were used to compare 1-year outcomes including survival, target artery patency, freedom from bleeding complication, freedom from all reinterventions, and freedom from stent-specific reintervention. RESULTS: Of the 1525 patients with complete exposure and outcome data, 49.6% were discharged on DAPT, 28.8% on SAPT, 13.6% on SAPT + anticoagulant, 3.2% on TT, 2.6% on anticoagulant alone, and 2.2% on no therapy. Discharge medication regimen was not associated with differences in 1-year survival, bleeding complications, composite reintervention rate, or stent-specific reintervention rate. However, there was a significant difference in 1-year target artery patency. On multivariable analysis comparing with SAPT, DAPT conferred a lower hazard of loss of target artery patency (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.27-0.84; P = .01). On sub-analyses of renal stents alone or visceral stents alone, DAPT no longer had a significantly lower hazard of loss of target artery patency (renal: HR, 0.66; 95% CI, 0.35-1.27; P = .22; visceral: HR, 0.31; 95% CI, 0.05-1.9; P = .21). Lastly, duration of DAPT therapy (1 month, 6 months, or 1 year) did not significantly affect target artery patency. CONCLUSIONS: Practice patterns for antiplatelet and anticoagulant regimens after F/BEVAR vary widely across the US-ARC. There were no differences in bleeding complications, survival or reintervention rates among different regimens, but higher branch vessel patency was noted in the DAPT cohort. These data suggest there is a benefit in DAPT therapy. However, the generalizability of this finding is limited by the retrospective nature of this data, and the clinical significance of this finding is unclear, as there is no difference in survival, bleeding, or reintervention rates amongst the different regimens. Hence, an "optimal" regimen, including the duration of such regimen, could not be clearly discerned. This suggests equipoise for a randomized trial, nested within this cohort, to identify the most effective antiplatelet/anticoagulant regimen for the growing number of patients being treated globally with F/BEVAR.
引用
- Fan EY, Schanzer A, Beck AW, et al. Practice patterns of antiplatelet and anticoagulant therapy after fenestrated/branched endovascular aortic repair. J Vasc Surg. 2024. PMID: 38796031. doi:10.1016/j.jvs.2024.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。